Globalstar, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on July 7, 2017, covering events occurring on June 30, 2017. Globalstar, Inc. entered into a Third Global Amendment and Restatement Agreement (2017 GARA) with Thermo Funding Company LLC and its lenders to restructure its debt facility and secure necessary equity capital.
Key Financial Metrics and Transactions
- Equity Raise: The company raised approximately $33 million in a Stage I equity raise via the sale of 17,837,838 shares of voting common stock to Thermo Funding II LLC at $1.85 per share (a 10% discount to the prior day's closing price).
- Total Equity Obligation: The company agreed to raise a total of $159 million in equity (the "2017 Equity Raise"), which includes the $12 million raised in January 2017 and the $33 million raised in June 2017. The remaining balance (Stage II) is due by October 30, 2017.
- Debt Restructuring Costs: The company paid an amendment fee of $255,000 and accelerated payment of approximately $21 million in restructuring fees and insurance premiums previously due on December 31, 2017.
- Liquidity Restrictions: 80% of all equity proceeds raised through December 31, 2019 must be deposited into a restricted account for Facility Agreement obligations.
Material Changes and Covenant Adjustments
The 2017 GARA introduced significant changes to the Facility Agreement:
- Covenant Deferrals: Certain financial covenants are deferred until the measurement period ending December 31, 2018.
- Equity Cure Extension: The deadline for Equity Cure Contributions is extended to the measurement period ending December 31, 2019.
- Debt Redemption: The requirement to redeem 8% Notes in full has been eliminated.
- Prepayment Deferral: Mandatory prepayments from qualifying equity raises are deferred until January 1, 2020.
- DSRA Revision: The Debt Service Reserve Account (DSRA) Required Balance definition was revised effective October 30, 2017, to equal the debt service due on the next repayment date.
- Capital Expenditure Cap: Capital expenditures related to spectrum rights are capped at the lesser of $20 million or 20% of aggregate equity proceeds raised between January 1, 2017, and December 31, 2019.
Outlook, Risks, and Contingencies
The filing indicates a critical dependency on completing the Stage II Equity Raise by October 30, 2017, to satisfy the total $159 million obligation. The company faces strict liquidity constraints, as the majority of raised capital is restricted for debt service. The transaction was approved by a special committee of independent directors. The sale of shares was conducted under Section 4(a)(2) of the Securities Act as a private placement, meaning the shares are restricted and cannot be transferred without registration or an exemption.
Investor Verification Checklist
- Verify the status of the Stage II Equity Raise required by October 30, 2017.
- Confirm the specific terms of the restricted account holding 80% of equity proceeds.
- Review the full text of the Third Amended and Restated Facility Agreement (Exhibit 10.2) for detailed covenant language.
- Assess the impact of the $21 million accelerated payment on current cash reserves.
- Monitor compliance with the new capital expenditure cap regarding spectrum rights.